Clinical trial
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.
NCT02348177 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.
- Lead sponsor
- Drugs for Neglected Diseases
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- December 31, 2016
- Enrollment
- 96 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.